Skip to content
  • Knowledge Hub
  • Careers
  • News & Events
  • Contact Us
CatSci CatSci
  • Home
  • Who we are
  • What we do
    • Small Molecule
      Early Development
    • Small Molecule
      Late Development
    • Route Scouting and Selection
    • High Potency APIs
    • Solid State & Preformulation
    • Analytical Science
    • Separation Science
    • Oligonucleotides
  • SmartPath
  • Digital Walkthrough
  • Knowledge Hub
  • Careers
  • News & Events
  • Contact Us

Process R&D

Categories
BlogBook ChaptersCase StudiesPapersPatentsPresentationsThought LeadersWebinarsWhitepapers
Tags
Analytical Chemistry Analytical Science Artificial Intelligence (AI) Biocatalysis Catalysis CatSci Paper CatSci Patent Chemical Development Design of Experiments Digital Drug Development Experimental Design Green Chemistry Industry insights Innovation Machine Learning (ML) Material Science Medium Throughput Experimentation Oligonucleotides Principal Component Analysis Process R&D PROTACs QbD Route Scouting and Selection Scale-up Scavenging Solvents Sustainability Technology transfer Work-up
3 CMC Challenges That Can Derail Your Programme

Rob Crook, our Director of Chemical Science, explores the 3 CMC Challenges that can derail your programme's success, along with strategies on how you can overcome scale-up risks, complexity, and speed-vs-strategy pitfalls.

Feb 18th 2025 By Rob Crook
How a New Synthetic Route Could Save You Time & Money

How expert route scouting and selection could save you time, money, and environmental impact.

2024 By Rob Crook
Synthesis and Development of a Nonaflate Ester in the Large-Scale Preparation of 3-Deoxymorp...

Letters in Organic Chemistry, 2024

2024 By Antonio M. RudaJonathan D. Moseley, et al.
Chemistry Today: High Potency Molecules: The Importance of Excellent Chemistry in their Succ...

CatSci's Director of Chemical Sciences, Rob Crook, and Senior Scientist, Jean-Baptiste Vendeville discuss the current considerations needed when developing a synthesis for a HPAPI, as well as the challenges faced by these complex molecules, in particular ADCs.

2024 By Jean-Baptiste VendevilleRob Crook
Route Selection Process and Tools: How to Find the Right Route for your API

Explore our interactive infographic to discover how you can leverage our process and tools to conduct a rigorous, objective route assessment that improves the scalability, efficiency, sustainability and quality of your synthesis

2024
Route Selection Excellence at CatSci

Discover our industry-leading route selection process and assessment tools.

2023 By Rob Crook
How to Successfully Accelerate Your Path to Clinic

Explore our interactive infographic to find out what you need to consider for each phase of development and get one step ahead with your molecule.

2023
Supporting Early Clinical Supply Through Process Development Excellence

Discover how CatSci rapidly developed a robust and inherently safe process which enabled our customer to support their early clinical supply without surprises or delays.

2023
Early Process Development and Scale-Up of Orally Active Apomorphine Drug Candidates

Org. Process Res. Dev. 2022

2022 By Antonio M. RudaEkaterina Y. MelikhovaJonathan D. MoseleyNadia Fleary-RobertsSiân M. ForsythSimon N. G. TylerSofia PapadouliVargini Thangavadivale, et al.
Application of the Polonovski Reaction: Scale-up of an Efficient and Environmentally Benign ...

Org. Process Res. Dev. 2022, 26, 5, 1398–1404

2022 By Antonio M. RudaSiân M. ForsythSofia PapadouliVargini Thangavadivale, et al.
Development of a Process to a 4-Arylated 2-Methylisoquinolin-1(2H)-one for the Treatment of ...

Org. Process Res. Dev. 2022, 26, 5, 1458–1469

2022 By Antonio M. RudaSiân M. Forsyth, et al.
Solvents In Scale-up Technical Piece – Part I

General points to consider on solvent selection for scale-up

2021 By CatSci team
The Next Decade of Drug Development 

Access the recordings of our 10-year anniversary symposium now. The event was centred on the future of medicines development and featured industry-leading speakers from AstraZeneca, Bristol Myers Squibb, DeepMatter, FogPharma, Merck, Novartis, R.I, Roche, Syngenta, and more.

2021
The Stability of Organometallics Technical Piece

Understanding their common decomposition pathways

2021 By CatSci team
Pharma Manufacturing: Pharma’s Shift Towards a Circular Economy

Our CCO, Dr Simon Tyler, argues that to achieve true sustainability, a more holistic approach to overall drug development is needed.

2021 By Simon N. G. Tyler
Fast UHPLC methods as a platform technology for expedited PR&D decision-making

CatSci's analytical team facilitated the development and deployment of an efficient and fast UHPLC method screening protocol.

2021 By Siân M. ForsythBeth Rees-HindleyDuncan ThompsonGareth Tutton
Solvents In Scale-up Technical Piece – Part II

Solvent Selection Considerations

2021 By CatSci team
Pharma’s Almanac: How Have Evolving Technologies Like Artificial Intelligence (AI) and...

The broader suite of computer-aided synthesis planning tools is increasingly catching up with chemists in its ability to establish the most suitable way of putting together a target active pharmaceutical ingredient.

2021 By Alan Steven
Chemical Development in Pharma 2: A CatSci Virtual Symposium 

Access the recordings of our second virtual symposium now. The event featured an impressive itinerary of three eminent speakers from industry, who delivered digestible 30-minute presentations, covering topics from high throughput experimentation in organic synthesis to separation technology and analytical science.

2021
Metal Scavenging Whitepaper

Development of a flow scavenging protocol

2021 By CatSci team
The Small Molecule Manufacturer: Solvents – Making the Green Choice

Dr Alan Steven explains why environmental sustainability and “big picture thinking” should be key considerations when selecting solvents for scale-up.

2021 By Alan Steven
1 2 3 Next »

Helpful Links

  • Contact Us
  • Careers
  • Safety, Health and Environment
  • Privacy Policy
  • CatSci Corporate and Social Responsibility (CSR) Policy
  • Sustainability Report 2024

What we do

  • Small Molecule Late Development
  • Small Molecule Early Development
  • Route Scouting and Selection
  • Analytical Science
  • High Potency APIs
  • Solid State and Preformulation
  • Oligonucleotides

Who we are

CatSci Ltd are an award-winning innovation partner for medicines development who are committed to creating tailored solutions from candidate selection through product launch and beyond. We break down the silos in small molecules, TACS, glues and oligonucleotides CMC development to accelerate the delivery of life-changing medicines to patients in need. 

© 2025 CatSci Ltd. All rights reserved.
Registered in England & Wales.
Company No. 07466141.